Management of the positive axilla in 2017 Eli AvisarTolga Ozmen Editorial 05 April 2017 Pages: 413 - 415
Prognosis of pregnancy-associated breast cancer Guek Eng LeeErica L. MayerAnn Partridge Review 01 April 2017 Pages: 417 - 421
Immunoglobulin-like domain 4-mediated ligand-independent dimerization triggers VEGFR-2 activation in HUVECs and VEGFR2-positive breast cancer cells Sheng ZhangXiaoping GaoLimin Yue Preclinical study 16 March 2017 Pages: 423 - 434
Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression Elena StrekalovaDmitry MalinVincent L. Cryns Preclinical study 21 March 2017 Pages: 435 - 447
A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells Yanyuan WuTrinh TranJaydutt V. Vadgama Preclinical study Open access 23 March 2017 Pages: 449 - 460
Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer Muhammad AsaduzzamanStephanie ConstantinouErnesto Yagüe Preclinical study Open access 24 March 2017 Pages: 461 - 474
ΔNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells Jitka HolcakovaMarta NekulovaPhilip J. Coates Preclinical study 27 March 2017 Pages: 475 - 484
FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer Zuhal HamurcuNermin KahramanBulent Ozpolat Preclinical study 30 March 2017 Pages: 485 - 493
Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69) Jenny FurlanettoChristian JackischGunter von Minckwitz Clinical trial 17 March 2017 Pages: 495 - 506
Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study Konstantinos TryfonidisS. MarreaudOn behalf of the EORTC- Breast Cancer Group Clinical trial 21 March 2017 Pages: 507 - 515
Quality of life in patients with recurrent breast cancer after second breast-conserving therapy in comparison with mastectomy: the German experience Svenja JendrianKatharina SteffensIsabell Witzel Clinical trial 21 March 2017 Pages: 517 - 526
Chemotherapy-induced irreversible alopecia in early breast cancer patients Gun Min KimSanghwa KimJoohyuk Sohn Clinical trial 21 March 2017 Pages: 527 - 533
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer José BaselgaSerafin M. MoralesHope S. Rugo Clinical trial 21 March 2017 Pages: 535 - 544
Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari) H. KawaguchiN. MasudaM. Toi Clinical trial 23 March 2017 Pages: 545 - 554
Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice Yu Jin LimSea-Won LeeIn Ah Kim Epidemiology 17 March 2017 Pages: 555 - 563
Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers Julia KrammerKatja Pinker-DomenigMaxine S. Jochelson Epidemiology 25 March 2017 Pages: 565 - 571
Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer Yaeji LimEun Sook KoSe Kyung Lee Epidemiology 27 March 2017 Pages: 573 - 586
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience Mariangela CiccareseAlessandra FabiGiammarco Surico Epidemiology 28 March 2017 Pages: 587 - 594
Self-reported long-term cardiac morbidity in breast cancer patients: a retrospective cohort study in Germany (PASSOS Heart Study) Daniel WollschlägerHiltrud MerzenichMaria Blettner Epidemiology 28 March 2017 Pages: 595 - 604
Is breast compression associated with breast cancer detection and other early performance measures in a population-based breast cancer screening program? Nataliia MoshinaSofie SebuødegårdSolveig Hofvind Epidemiology 29 March 2017 Pages: 605 - 613
Relationship of breast MRI to recurrence rates in patients undergoing breast-conservation treatment Maureen V. HillJulia L. BeemanRichard J. Barth Jr. Brief Report 18 March 2017 Pages: 615 - 622
Aromatase expression in atypical ductal hyperplasia in women R. J. SantenD. C. RadiskyH. Sasano Brief Report 23 March 2017 Pages: 623 - 629
Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer Paola MutiGiorgio SecretoVittorio Krogh Letter to the Editor 18 March 2017 Pages: 631 - 632
Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting K. Matter-WalstraM. SchwenkglenksK. J. Dedes Letter to the Editor 21 March 2017 Pages: 635 - 635
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials M. V. DieciA. FrassoldatiV. Guarneri Erratum 03 April 2017 Pages: 637 - 637
Erratum to: ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling Luca GelsominoGuowei GuSuzanne A. W. Fuqua Erratum 24 April 2017 Pages: 639 - 640
